

# Leucemia linfatica cronica

Francesca R Mauro Dipartimento di Medicina Traslazionale e di Precisione Università Sapienza, Roma

# ROMA



## **Disclosures of FR MAURO**


	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Janssen					x	x	
AstraZeneca					x	x	
Abbvie	x				x	x	
Beigene						x	
Takeda	x				x	x	


HOT NEWS

	НОТ	NEWS
	Ibrutinib	Resonate-2 ECOG E1912
Chronic	Acalabrutinib	ASCEND ELEVATE TN ELEVATE R/R
Lymphocytic Leukemia	Zanubrutinib	SEQUOIA coohort 1- arm B SEQUOIA coohort 2- arm C ALPINE
	Pirtobrutinib	BRUIN trial
	Venetoclax-obinuruzumab	CLL14
	Venetoclax-ibrutinib	CAPTIVATE GLOW CLL13 ( Gaia) FLAIR

IN HEMATOLOGY Sindromi linfoproliferative ed oltre...


HOT NEWS






Patients on the IR arm also had superior PFS in both IGHV unmutated (HR = 0.27, P < .001) and IGHV mutated subgroups

Shanafelt TD, et al. Blood 2022




## ASCEND TRIAL: ACALABRUTINIB IN R/R PATIENTS WITH CLL: 4 YEAR UPDATED RESULTS



Months

## Investigator-Assessed PFS by IGHV



Jurczak et al. ASCO 2022

Investigator-Assessed PFS in Patient Subgroups (Acala vs IdR/BR)

IN HEMATOLOGY

ed oltre...


Sindromi linfoproliferative


HOT NEWS


Number of Events/Subjects Hazard Ratio (95% CI) Subgroup Analysis Acala IdR/BR Overall 62/15 119/155 0.28 (0.20, 0.38) Age group <65 years ≥65 years 0.23 (0.14, 0.39) 0.33 (0.23, 0.49) 21/58 46/57 ----Sex Male Female 45/108 80/100 ----0.30 (0.20, 0.43) 0.26 (0.15, 0.47) ECOG at randomizati 57/137 5/18 103/135 --0.30 (0.22, 0.42) 0.22 (0.08, 0.61) Rai Stage at screening Stage 0–II Stage III–IV ----37/90 67/90 52/64 0.32 (0.22, 0.49) Sulky disease
<5 cm
≥5 cm</pre> ----0.34 (0.22, 0.53) 0.22 (0.14, 0.35) 30/79 32/76 56/80 63/75 Number of prior therapies 53/139 9/16 103/138 ----0.28 (0.20, 0.39) 1-3 ≥4 Presence of del(17p) Yes 12/28 0.13 (0.06, 0.29) 22/26 -TP53 mutation Yes No 18/39 43/113 0.25 (0.14, 0.46) 0.28 (0.19, 0.41) 29/34 ----IGHV Mutated Unmutated 0.34 (0.13, 0.93) 0.29 (0.20, 0.41) 6/21 47/109 11/17 93/119 -----Complex Karyotype Yes No 3/3 2/3 60/150 0.18 (0.02, 1.84) 0.28 (0.21, 0.39) 0.05 0.5 Favors acala + Favors IdR/BR



Months









## Common Adverse Events (≥12% of Patients in Any Arm)

	<u>Arm A</u> Zanubrutinib (n=240ª)		<u>Arm B</u> Bendamustine + Rituxim (n=227ª)	
AE, n (%)	Any Grade	Grade ≥3	Any Grade	Grade
Contusion	46 (19.2)	0 (0.0)	8 (3.5)	0 (0.0
Upper respiratory tract infection	41 (17.1)	2 (0.8)	27 (11.9)	2 (0.9
Neutropenia <sup>b</sup>	37 (15.4)	27 (11.3)	129 (56.8)	116 (51
Diarrhea	33 (13.8)	0 (0.0)	30 (13.2)	4 (1.8
Arthralgia	32 (13.3)	2 (0.8)	20 (8.8)	1 (0.4
Fatigue	28 (11.7)	3 (1.3)	36 (15.9)	2 (0.9
Rash	26 (10.8)	0 (0.0)	44 (19.4)	6 (2.6
Constipation	24 (10.0)	1 (0.4)	43 (18.9)	0 (0.0
Nausea	24 (10.0)	0 (0.0)	74 (32.6)	3 (1.3
Pyrexia	17 (7.1)	0 (0.0)	60 (26.4)	8 (3.5
Vomiting	17 (7.1)	0 (0.0)	33 (14.5)	3 (1.3
Anemia	11 (4.6)	1 (0.4)	43 (18.9)	4 (1.8
Thrombocytopenia	9 (3.8)	4 (1.7)	31 (13.7)	16 (7.
Infusion-related reaction <sup>c</sup>	1 (0.4)	0 (0.0)	43 (18.9)	6 (2.6




Tam et al., ASH 2021



Tam et al.ASH 2021

IN HEMATOL **SEQUOIA TRIAL:** 1L Zanubrutinib+ Venetoclax in patients with del (17p)




HOT


NEWS

Sindromi lin

ed oltre...




## Median Follow-Up: 12.0 Months



Tedeschi et al., ASH 2021

ALPINE TRIAL: Ibrutinib vs Zanubrutinib in Patients With R/R CLL




IN HEMATOLOGY

ed oltre...

Sindromi linfoproliferative

HOT


NEWS



Response

Hillmen et al. EHA 2021

### ELEVATE R/R: ACALABRUTINIB VS. IBRITINIB IN R/R PATIENTS WITH CLL Sindromi linfoprolifera




	Any	grade	Grade ≥3		
	Acalabrutinib (n=266)	lbrutinib (n=263)	Acalabrutinib (n=266)	lbrutinib (n=263)	
Cardiac events	64 (24.1)	79 (30.0)	23 (8.6)	25 (9.5)	
Atrial fibrillation <sup>a*</sup>	25 (9.4)	42 (16.0)	13 (4.9)	10 (3.8)	
Ventricular arrhythmias <sup>b</sup>	0	3 (1.1)	0	1 (0.4)	
Bleeding events*	101 (38.0)	135 (51.3)	10 (3.8)	12 (4.6)	
Major bleeding events <sup>c</sup>	12 (4.5)	14 (5.3)	10 (3.8)	12 (4.6)	
Hypertension <sup>d</sup> *	25 (9.4)	61 (23.2)	11 (4.1)	24 (9.1)	
Infections <sup>e</sup>	208 (78.2)	214 (81.4)	82 (30.8)	79 (30.0)	
ILD/pneumonitis*	7 (2.6)	17 (6.5)	1 (0.4)	2 (0.8)	
SPMs excluding NMSC	24 (9.0)	20 (7.6)	16 (6.0)	14 (5.3)	

IN HEMATOLOGY

ed oltre...

HOT

NEWS



Byrd, et al. JCO 2021




## IN HEMATOLO Sindromi linfopr PIRTOBRUTINIB IN R/R PATIENTS WITH CLL PREVIOUSLY TREATED WITH BTKI




Characteristics	N = 261
Median age, years (range)	69 (36-88)
Female, n (%)	84 (32)
Male, n (%)	177 (68)
ECOG PSª, n (%)	
0	138 (53)
1	104 (40)
2	19 (7)
Median number of prior lines of systemic therapy	3 (1-11)
(range)	
Prior therapy, n (%)	
BTK inhibitor	261 (100)
Anti-CD20 antibody	230 (88)
Chemotherapy	207 (79)
BCL2 inhibitor	108 (41)
PI3K inhibitor	51 (20)
CAR-T	15 (6)
Stem cell transplant	6 (2)
Allogeneic stem cell transplant	5 (2)
Autologous stem cell transplant	1 (<1)
Reason discontinued prior BTKi, n (%)	
Progressive disease	196 (75)
Toxicity/Other	65 (25)

Mutation status, n (%)	
BTK C481-mutant	89 (43)
BTK C481-wildtype	118 (57)
PLCG2-mutant	33 (16)
High Risk Molecular Features, n (%)	
17p deletion	51 (28)
TP53 mutation	64 (37)
17p deletion or TP53 mutation	77 (36)
Both 17p deletion and TP53 mutation	38 (27)
IGHV unmutated	168 (84)
11g deletion	45 (25)

## **Responses over time**





## **Safety Profile**

	Treatment-emergent AEs, (≥15%), %					
Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Any Grade	
Fatigue	13%	8%	1%	-	23%	
Diarrhea	15%	4%	<1%	<1%	19%	
Neutropeniaª	1%	2%	8%	6%	18%	
Contusion	15%	2%	-	-	17%	
AEs of special interest <sup>b</sup>						
Bruising <sup>c</sup>	20%	2%		-	22%	
Rash <sup>d</sup>	9%	2%	<1%	-	11%	
Arthralgia	8%	3%	<1%	-	11%	
Hemorrhage <sup>e</sup>	5%	2%	1% <sup>g</sup>	-	8%	
Hypertension	1%	4%	2%	-	7%	
Atrial fibrillation/flutter <sup>f</sup>	-	1%	<1%	<1%	2% <sup>h</sup>	

## Mato et al., EHA 2022



IN HEMATOL

#### Median age, years (range) 69 (36-88) Female, n (%) 84 (32) 177 (68) Male, n (%) ECOG PS<sup>a</sup>, n (%) 138 (53) 104 (40) 19 (7) 3 (1-11) Median number of prior lines of systemic therapy (range) Prior therapy, n (%) BTK inhibitor 261 (100) Anti-CD20 antibody 230 (88) Chemotherapy 207 (79) BCL2 inhibitor 108 (41) PI3K inhibitor 51 (20) CAR-T 15 (6) Stem cell transplant 6(2) Allogeneic stem cell transplant 5(2) Autologous stem cell transplant 1 (<1) Reason discontinued prior BTKi, n (%) Progressive disease 196 (75) 65 (25) Toxicity/Other


N = 261


Characteristics

Mutation status, n (%)	
BTK C481-mutant	89 (43)
BTK C481-wildtype	118 (57)
PLCG2-mutant	33 (16)
ligh Risk Molecular Features, n (%)	
17p deletion	51 (28)
TP53 mutation	64 (37)
17p deletion or TP53 mutation	77 (36)
Both 17p deletion and TP53 mutation	38 (27)
IGHV unmutated	168 (84)
11g deletion	45 (25)

PIRTOBRUTINIB IN R/R PATIENTS WITH CLL PREVIOUSLY TREATED WITH BTKI

## **Responses over time**







## **Safety Profile**

	Treatment-emergent AEs, (≥15%), %					
Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Any Grade	
Fatigue	13%	8%	1%	-	23%	
Diarrhea	15%	4%	<1%	<1%	19%	
Neutropeniaª	1%	2%	8%	6%	18%	
Contusion	15%	2%		-	17%	
AEs of special interest <sup>b</sup>						
Bruising <sup>c</sup>	20%	2%	-	-	22%	
Rash <sup>d</sup>	9%	2%	<1%	-	11%	
Arthralgia	8%	3%	<1%	-	11%	
Hemorrhage <sup>e</sup>	5%	2%	1% <sup>g</sup>	-	8%	
Hypertension	1%	4%	2%	-	7%	
Atrial fibrillation/flutter <sup>f</sup>	-	1%	<1%	<1%	2% <sup>h</sup>	

Mato et al., EHA 2022







IN HEMATOLOGY

HOT

## THE CLL13-GAIA TRIAL IN TN PATIENTS WITH CLL





Deep responses observed in both BM and PB in patients with uIGHV

Munir. ASH 2021

IN HEMATOLOGY HOT CAPTIVATE TRIAL: 1L ibrutinib plus venetoclax- FD cohort, 3-year FU Sindromi linfoproliferative NEWS ed oltre... All Treated Characteristic Patients (n = 159) Median age, yr (range) 60 (33-71) MRD-guided randomization Placebo Confirmed uMRD High-risk features, n (%) Randomize 1:1 (double-blind) Ibrutinib 12 cycles MRD Unmutated IGHV 89 (56) ibrutinib + del(17p)/TP53 mutation 27 (17) N=164 lead-in venetoclax uMRD Not Confirmed Ibrutinib del(17p) 20 (13) del(11q)\* 28 (18) Randomize 1:1 (open-label) Ibrutinib + Venetoclax Complex karyotype<sup>†</sup> 31 (19) 12 cycles FD PFS<sup>a</sup> ibrutinib ibrutinib + N=159 lead-in venetoclax 100 All treated patients **3 Months Posttreatment 12 Months Posttreatment** 90 \* 100 -96% 80 Progression-Free Survival, del(17p)/TP53 Unmutated 100 mutated Treatment 70 IGHV 80 43% period 57% 80 60 CR<sup>a</sup> 56% CR<sup>a</sup> 64% CR<sup>a</sup> 57% 60 Percent 50 % 60 Patients, 40 40 40% 40 del(17p)/TP53 Unmutated All Treated 30 mutated IGHV Patients 38% n=27 n=89 N=159 PR<sup>b</sup> 41% PR⁵ 33% PR<sup>b</sup> 39% 20 20 20 36-month 11% 80 86 88 PFS rate, % 10 6% 6% (58-91) (77-92) (82 - 92)0 (95% CI) 0 del(17p)/TP53 mutated Unmutated IGHV All treated patients N=159 uMRD\* rates with VenI n=27 n=89 0 15 18 21 24 27 30 33 36 0 3 6 9 12 Response rates with Ven I uMRD; <10<sup>-4</sup> Months dMRD; ≥10<sup>-4</sup> Off MRD Follow-up<sup>a</sup> Ghia. et al., ASCO 2021; Moreno et al., EHA 2022 Missing Data

## FLAIR randomized trial **ibrutinib vs. ibrutinib+venetoclax**

- Pts <75 yrs or with <20% 17p

HOT

NEWS

- Duration of therapy defined by MRD with treatment
- for up to 6 years, the earliest therapy could stop was 2 years

MRD assessed centrally by FC in PB and BM


IN HEMATOLOGY

Sindromi linfoprolifer

ed oltre...

## Interim analysis in the first 274 pts

(I [n=138] and I+V [n=136]) reaching 2 yrs post-randomisation.




In ibrutinib and ibrutinib+venetoclax arms: PB MRD every 6 months. If PB MRD negative repeat after 3 months and then PB and BM at 6 months – if all MRD negative then first PB MRD negative result is time to MRD negativity. **Duration of therapy – double time to MRD negativity (minimum 2 years; maximum 6 years)** 

## iwCLL Response at 9 months

1L IBRUTINIB+ VENETOCLAX: INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL



## Primary endpoint: uMRD at 2 years



Hillmen et al., EHA 2022

# **CLL: HOT NEWS- SUMMARY**

Long term responses with BTKi

EMATOL OGY

Sindromi linfoproliferative

ed oltre...

HOT

NEWS

Second-generation and investigational BTKis offer higher selectivity with the improved safety profile and outcomes

Pirtobrutinib improved outcomes and efficacy in patients with BTKi-resistant CLL

Venetoclax and BTKi combinations produce deep responses further improves PFS outcomes



Roma, 17 Giugno 2022 Starhotels Metropole

# Grazie